Dyne Therapeutics Inc. (NASDAQ:DYN) stands out as one of the top stocks priced under $20. On September 29, the company revealed that Japan’s Ministry of Health, Labour and Welfare (MHLW) has awarded Orphan Drug designation for its investigational drug, DYNE-251, specifically aimed at treating patients with Duchenne muscular dystrophy (DMD) who possess mutations in the DMD gene suitable for exon 51 skipping.
Doug Kerr, the Chief Medical Officer of the company, pointed out that data from the ongoing DELIVER trial indicate remarkable and sustained improvements in functionality over 18 months, attributed to considerable dystrophin expression.
DYNE-251 is currently under evaluation in the global, randomized, placebo-controlled, double-blind Phase 1/2 DELIVER clinical trial. The Orphan Drug designation in Japan pertains to medications intended for treating rare diseases that impact fewer than 50,000 patients and address significant medical needs.
Dyne Therapeutics Inc. (NASDAQ:DYN) is a company focused on clinical-stage therapies for neuromuscular disorders, working actively on discoveries and developments in the U.S. market.
Although we recognize the investment potential of DYN, we contend that certain AI stocks present a more favorable upside and reduce downside risks. If you’re seeking an exceptionally undervalued AI stock that stands to gain notably from Trump-era tariffs and the trend of onshoring, check out our complimentary report on the top short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article originally appeared on Insider Monkey.
